Sex Differences in Cardiovascular Disease and Cognitive Impairment: Another Health Disparity for Women?

Annabelle Santos Volgman, C Noel Bairey Merz, Neelum T Aggarwal, Vera Bittner, T Jared Bunch, Philip B Gorelick, Pauline Maki, Hena N Patel, Athena Poppas, Jeremy Ruskin, Andrea M Russo, Shari R Waldstein, Nanette K Wenger, Kristine Yaffe, Carl J Pepine, Annabelle Santos Volgman, C Noel Bairey Merz, Neelum T Aggarwal, Vera Bittner, T Jared Bunch, Philip B Gorelick, Pauline Maki, Hena N Patel, Athena Poppas, Jeremy Ruskin, Andrea M Russo, Shari R Waldstein, Nanette K Wenger, Kristine Yaffe, Carl J Pepine

No abstract available

Keywords: APOE; Alzheimer disease; cardiac procedures; complication; dementia; ischemic heart disease; strokes.

Figures

Figure 1
Figure 1
Event‐free survival estimates for dementia incidence among categories of percent time anticoagulation with vitamin K antagonists is in the therapeutic range. Reprinted from Jacobs et al60 with permission. Copyright ©2014, Elsevier.
Figure 2
Figure 2
Factors that contribute to the findings that women have a higher proportion of the population with dementia. AD indicates Alzheimer disease; AF, atrial fibrillation; CABG, coronary artery bypass graft surgery; CV RF, cardiovascular risk factors; DM, diabetes mellitus; HTN, hypertension; TAVR, transcatheter aortic valve replacement.

References

    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e66.
    1. Alzheimer's Association 2019 Alzheimer's disease facts and figures. Alzheimers Dement. 2019;15:321–387. Available at: Accessed August 2, 2019.
    1. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology. 2007;69:2197–2204.
    1. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200–208.
    1. Committee on family caregiving for older adults In: Schulz R, Eden J, eds. Families Caring for an Aging America. Washington, DC: National Academies Press (US); 2016: Nov. 8, 2016. Copyright 2016 by the National Academy of Sciences. All rights reserved. ISBN‐13: 978‐0‐309‐44806‐2ISBN‐10: 0‐309‐44806‐9. Available at: .
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison‐Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–292.
    1. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171–186.
    1. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–562.
    1. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–367.
    1. Petersen RC, Lopez O, Armstrong MJ, Getchius TS, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:126–135.
    1. Au B, Dale‐McGrath S, Tierney MC. Sex differences in the prevalence and incidence of mild cognitive impairment: a meta‐analysis. Ageing Res Rev. 2017;35:176–199.
    1. Chene G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, Seshadri S. Gender and incidence of dementia in the Framingham Heart Study from mid‐adult life. Alzheimers Dement. 2015;11:310–320.
    1. Sundermann EE, Maki PM, Rubin LH, Lipton RB, Landau S, Biegon A. Female advantage in verbal memory: evidence of sex‐specific cognitive reserve. Neurology. 2016;87:1916–1924.
    1. Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, Mallampalli MP, Mormino EC, Scott L, Yu WH, Maki PM, Mielke MM. Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimers Dement. 2018;14:1171–1183.
    1. Pool LR, Weuve J, Wilson RS, Bultmann U, Evans DA, Mendes de Leon CF. Occupational cognitive requirements and late‐life cognitive aging. Neurology. 2016;86:1386–1392.
    1. Fisher GG, Stachowski A, Infurna FJ, Faul JD, Grosch J, Tetrick LE. Mental work demands, retirement, and longitudinal trajectories of cognitive functioning. J Occup Health Psychol. 2014;19:231–242.
    1. Kasper JD, Freedman VA, Spillman BC, Wolff JL. The disproportionate impact of dementia on family and unpaid caregiving to older adults. Health Aff. 2015;34:1642–1649.
    1. Elias MF, Goodell AL, Dore GA. Hypertension and cognitive functioning: a perspective in historical context. Hypertension. 2012;60:260–268.
    1. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H, Knopman DS, Launer LJ, Saczynski JS, Seshadri S, Zeki Al Hazzouri A. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67–e94.
    1. Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19:24.
    1. Perrotta M, Lembo G, Carnevale D. Hypertension and dementia: epidemiological and experimental evidence revealing a detrimental relationship. Int J Mol Sci. 2016;17:347.
    1. Waldstein SR, Wendell CR. Neurocognitive function and cardiovascular disease. J Alzheimers Dis. 2010;20:833–842.
    1. Waldstein SR. Hypertension and neuropsychological function: a lifespan perspective. Exp Aging Res. 1995;21:321–352.
    1. Lande MB, Kupferman JC, Adams HR. Neurocognitive alterations in hypertensive children and adolescents. J Clin Hypertens (Greenwich). 2012;14:353–359.
    1. Rovio SP, Pahkala K, Nevalainen J, Juonala M, Salo P, Kähönen M, Hutri‐Kähönen N, Lehtimäki T, Jokinen E, Laitinen T. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns Study. J Am Coll Cardiol. 2017;69:2279–2289.
    1. Waldstein SR, Manuck SB, Ryan CM, Muldoon MF. Neuropsychological correlates of hypertension: review and methodologic considerations. Psychol Bull. 1991;110:451.
    1. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B, Dartigues JF, Vellas B, Andrieu S. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta‐analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29:113–130.
    1. Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Press. 2018;27:247.
    1. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators . Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174:324–333.
    1. Kritz‐Silverstein D, Laughlin GA, McEvoy LK, Barrett‐Connor E. Sex and age differences in the association of blood pressure and hypertension with cognitive function in the elderly: the Rancho Bernardo Study. J Prev Alzheimers Dis. 2017;4:165–173.
    1. Gilsanz P, Mayeda ER, Glymour MM, Quesenberry CP, Mungas DM, DeCarli C, Dean A, Whitmer RA. Female sex, early‐onset hypertension, and risk of dementia. Neurology. 2017;89:1886–1893.
    1. Zilberman JM, Cerezo GH, Del Sueldo M, Fernandez‐Perez C, Martell‐Claros N, Vicario A. Association between hypertension, menopause, and cognition in women. J Clin Hypertens (Greenwich). 2015;17:970–976.
    1. Stefanidis KB, Askew CD, Greaves K, Summers MJ. The effect of non‐stroke cardiovascular disease states on risk for cognitive decline and dementia: a systematic and meta‐analytic review. Neuropsychol Rev. 2018;28:1–15.
    1. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39:2396–2399.
    1. Gorelick PB. Distribution of atherosclerotic cerebrovascular lesions. Effects of age, race, and sex. Stroke. 1993;24:I16–I19; discussion I20–1.
    1. Joakimsen O, Bonaa KH, Stensland‐Bugge E, Jacobsen BK. Population‐based study of age at menopause and ultrasound assessed carotid atherosclerosis: the Tromso Study. J Clin Epidemiol. 2000;53:525–530.
    1. Pu Y, Liu L, Wang Y, Zou X, Pan Y, Soo Y, Leung T, Zhao X, Wong KS, Wang Y. Geographic and sex difference in the distribution of intracranial atherosclerosis in China. Stroke. 2013;44:2109–2114.
    1. Kasner SE, Chimowitz MI, Lynn MJ, Howlett‐Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Benesch CG, Sila CA, Jovin TG, Romano JG, Cloft HJ. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113:555–563.
    1. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR. Cardiovascular risk factors and cognitive decline in middle‐aged adults. Neurology. 2001;56:42–48.
    1. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–551.
    1. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–2713.
    1. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol. 2003;23:2055–2062.
    1. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322:141–147.
    1. Bos D, van der Rijk MJ, Geeraedts TE, Hofman A, Krestin GP, Witteman JC, van der Lugt A, Ikram MA, Vernooij MW. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke. 2012;43:1878–1884.
    1. Taqueti VR. Sex differences in the coronary system. Adv Exp Med Biol. 2018;1065:257–278.
    1. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salman RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, Gonzalez HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Roman GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV. Vascular dysfunction—the disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019;15:158–167.
    1. Vidal JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Thorgeirsson G, Kjartansson O, Garcia ME, van Buchem MA, Harris TB, Gudnason V, Launer LJ. Coronary artery calcium, brain function and structure: the AGES‐Reykjavik Study. Stroke. 2010;41:891–897.
    1. Bos D, Vernooij MW, de Bruijn RF, Koudstaal PJ, Hofman A, Franco OH, van der Lugt A, Ikram MA. Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline. Alzheimers Dement. 2015;11:639–647.e1.
    1. Schmidt KMT, Nan J, Scantlebury DC, Aggarwal NR. Stable ischemic heart disease in women. Curr Treat Options Cardiovasc Med. 2018;20:72.
    1. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2018;72:2625–2641.
    1. Roberts RO, Knopman DS, Geda YE, Cha RH, Roger VL, Petersen RC. Coronary heart disease is associated with non‐amnestic mild cognitive impairment. Neurobiol Aging. 2010;31:1894–1902.
    1. Ahto M, Isoaho R, Puolijoki H, Laippala P, Sulkava R, Kivela SL. Cognitive impairment among elderly coronary heart disease patients. Gerontology. 1999;45:87–95.
    1. Gharacholou SM, Reid KJ, Arnold SV, Spertus J, Rich MW, Pellikka PA, Singh M, Holsinger T, Krumholz HM, Peterson ED, Alexander KP. Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients’ health status registry. Am Heart J. 2011;162:860–869.e1.
    1. Golive A, May HT, Bair TL, Jacobs V, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Weiss JP, Bunch TJ. The impact of gender on atrial fibrillation incidence and progression to dementia. Am J Cardiol. 2018;122:1489–1495.
    1. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta‐analysis. Neurology. 2011;76:914–922.
    1. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta‐analysis. Ann Intern Med. 2013;158:338–346.
    1. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7:915–926.
    1. Gargano JW, Reeves MJ; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators . Sex differences in stroke recovery and stroke‐specific quality of life: results from a statewide stroke registry. Stroke. 2007;38:2541–2548.
    1. Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, Crandall BG, Day JD, Johanning K, Long Y. Time outside of therapeutic range in atrial fibrillation patients is associated with long‐term risk of dementia. Heart Rhythm. 2014;11:2206–2213.
    1. Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ. Long‐term population‐based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long‐term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016;118:210–214.
    1. Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN, Masoudi FA, Turchin A, Song Y, Doros G, Davis MB, Daugherty SL. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6:e005801 DOI: 10.1161/JAHA.117.005801.
    1. National Institute of Health . Guidelines on the inclusion of women and minorities as subjects in clinical research. 1994;59:14504–14513.
    1. Graves KG, May HT, Jacobs V, Bair TL, Stevens SM, Woller SC, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Peter Weiss J, Jared Bunch T. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long‐term warfarin. Am Heart J. 2017;188:93–98.
    1. Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M, Ruskin JN. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta‐analysis. Ann Intern Med. 2014;161:650–658.
    1. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, Bergamasco L, Boffano C, Valentini MC, Cesarani F, Scaglione M. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol. 2013;62:1990–1997.
    1. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39:453–460.
    1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140:e125–e151.
    1. Leng Y, McEvoy CT, Allen IE, Yaffe K. Association of sleep‐disordered breathing with cognitive function and risk of cognitive impairment: a systematic review and meta‐analysis. JAMA Neurol. 2017;74:1237–1245.
    1. Chiu HY, Lai FC, Chen PY, Tsai PS. Differences between men and women aged 65 and older in the relationship between self‐reported sleep and cognitive impairment: a nationwide survey in Taiwan. J Am Geriatr Soc. 2016;64:2051–2058.
    1. Vogels RL, Scheltens P, Schroeder‐Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail. 2007;9:440–449.
    1. Bennett SJ, Sauvé MJ. Cognitive deficits in patients with heart failure: a review of the literature. J Cardiovasc Nurs. 2003;18:219–242.
    1. Gure TR, Blaum CS, Giordani B, Koelling TM, Galecki A, Pressler SJ, Hummel SL, Langa KM. Prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc. 2012;60:1724–1729.
    1. Tibrewala A, Yancy CW. Heart failure with preserved ejection fraction in women. Heart Fail Clin. 2019;15:9–18.
    1. Cogswell RJ, Norby FL, Gottesman RF, Chen LY, Solomon S, Shah A, Alonso A. High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2017;19:1303–1309.
    1. Dolansky MA, Hawkins MA, Schaefer JT, Sattar A, Gunstad J, Redle JD, Josephson R, Moore SM, Hughes JW. Association between poorer cognitive function and reduced objectively monitored medication adherence in patients with heart failure. Circ Heart Fail. 2016;9:e002475.
    1. Gress DR. The problem with asymptomatic cerebral embolic complications in vascular procedures: what if they are not asymptomatic? J Am Coll Cardiol. 2012;60:1614–1616.
    1. Kodali S, Williams MR, Doshi D, Hahn RT, Humphries KH, Nkomo VT, Cohen DJ, Douglas PS, Mack M, Xu K, Svensson L, Thourani VH, Tuzcu EM, Weissman NJ, Leon M, Kirtane AJ. Sex‐specific differences at presentation and outcomes among patients undergoing transcatheter aortic valve replacement: a cohort study. Ann Intern Med. 2016;164:377–384.
    1. Chaker Z, Badhwar V, Alqahtani F, Aljohani S, Zack CJ, Holmes DR, Rihal CS, Alkhouli M. Sex differences in the utilization and outcomes of surgical aortic valve replacement for severe aortic stenosis. J Am Heart Assoc. 2017;6:e006370 DOI: 10.1161/JAHA.117.006370.
    1. Goto T, Baba T, Ito A, Maekawa K, Koshiji T. Gender differences in stroke risk among the elderly after coronary artery surgery. Anesth Analg. 2007;104:1016–1022, tables of contents.
    1. Auffret V, Campelo‐Parada F, Regueiro A, Del Trigo M, Chiche O, Chamandi C, Allende R, Cordoba‐Soriano JG, Paradis JM, De Larochelliere R, Doyle D, Dumont E, Mohammadi S, Cote M, Marrero A, Puri R, Rodes‐Cabau J. Serial changes in cognitive function following transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:2129–2141.
    1. Itchhaporia D. Transcatheter aortic valve replacement in women. Clin Cardiol. 2018;41:228–231.
    1. Singer I, van der Laken J, Edmonds HL Jr, Slater AD, Austin E, Shields CB, Kupersmith J. Is defibrillation testing safe? Pacing Clin Electrophysiol. 1991;14:1899–1904.
    1. Vriens EM, Bakker PF, Vries JW, Wieneke GH, Van Huffelen AC. The impact of repeated short episodes of circulatory arrest on cerebral function. Reassuring electroencephalographic (EEG) findings during defibrillation threshold testing at defibrillator implantation. Electroencephalogr Clin Neurophysiol. 1996;98:236–242.
    1. Halas K, Krzyzanowski K, Krzyzanowska E, Smurzynski P, Ryczek R, Michalkiewicz D, Orski Z, Makowski K, Wierzbowski R, Gielerak G. Cognitive impairment after appropriate implantable cardioverter‐defibrillator therapy for ventricular fibrillation. Kardiol Pol. 2014;72:134–139.
    1. Benedini G, Marchini A, Curnis A, Bianchetti F, Gardini A, Pinetti P, Zanelli E. Implantable defibrillation and thromboembolic events. Pacing Clin Electrophysiol. 1995;18:199–202.
    1. Edwards FH, Carey JS, Grover FL, Bero JW, Hartz RS. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg. 1998;66:125–131.
    1. Khan SS, Nessim S, Gray R, Czer LS, Chaux A, Matloff J. Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. Ann Intern Med. 1990;112:561–567.
    1. Pina IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, Velazquez EJ, Pai RG, Cyrille N, Lee KL, Desvigne‐Nickens P. Sex difference in patients with ischemic heart failure undergoing surgical revascularization: results from the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2018;137:771–780.
    1. Hogue CW Jr, Barzilai B, Pieper KS, Coombs LP, DeLong ER, Kouchoukos NT, Davila‐Roman VG. Sex differences in neurological outcomes and mortality after cardiac surgery: a society of thoracic surgery national database report. Circulation. 2001;103:2133–2137.
    1. Newman MF, Kirchner JL, Phillips‐Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA. Longitudinal assessment of neurocognitive function after coronary‐artery bypass surgery. N Engl J Med. 2001;344:395–402.
    1. Kennedy ED, Choy KC, Alston RP, Chen S, Farhan‐Alanie MM, Anderson J, Ang YL, Moore DE, MacKenzie SA, Sykes RA. Cognitive outcome after on‐and off‐pump coronary artery bypass grafting surgery: a systematic review and meta‐analysis. J Cardiothorac Vasc Anesth. 2013;27:253–265.
    1. Benvenuti SM, Patron E, Zanatta P, Polesel E, Bonfà C, Palomba D. Change in behavioral functional capacity is associated with preexisting cognitive function rather than with cognitive decline in patients 1 year after cardiac surgery. Gen Hosp Psychiatry. 2013;35:117–121.
    1. Hogue CW, Lillie R, Hershey T, Birge S, Nassief AM, Thomas B, Freedland KE. Gender influence on cognitive function after cardiac operation. Ann Thorac Surg. 2003;76:1119–1125.
    1. Elharram M, Dayan N, Kaur A, Landry T, Pilote L. Long‐term cognitive impairment after preeclampsia: a systematic review and meta‐analysis. Obstet Gynecol. 2018;132:355–364.
    1. Shumaker S, Legault C, Kuller L, Rapp S, Thal L, Lane D, Fillit H, Stefanick M, Hendrix S, Lewis C, Masaki K, Coker L; Women's Health Initiative Memory Study . Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947–2958.
    1. Coker LH, Espeland MA, Hogan PE, Resnick SM, Bryan RN, Robinson JG, Goveas JS, Davatzikos C, Kuller LH, Williamson JD, Bushnell CD, Shumaker SA ; WHIMS‐MRI Study Group . Change in brain and lesion volumes after CEE therapies: the WHIMS‐MRI studies. Neurology. 2014;82:427–434.
    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
    1. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski‐Wende J; WHI Investigators . Menopausal hormone therapy and long‐term all‐cause and cause‐specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318:927–938.
    1. Espeland MA, Brinton RD, Hugenschmidt C, Manson JE, Craft S, Yaffe K, Weitlauf J, Vaughan L, Johnson KC, Padula CB, Jackson RD, Resnick SM; WHIMS Study Group . Impact of type 2 diabetes and postmenopausal hormone therapy on incidence of cognitive impairment in older women. Diabetes Care. 2015;38:2316–2324.
    1. Aggarwal NR, Patel HN, Mehta LS, Sanghani RM, Lundberg GP, Lewis SJ, Mendelson MA, Wood MJ, Volgman AS, Mieres JH. Sex differences in ischemic heart disease: advances, obstacles, and next steps. Circ Cardiovasc Qual Outcomes. 2018;11:e004437.
    1. Daulatzai MA. Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's disease. Neurotox Res. 2013;24:407–459.
    1. Aday AW, Ridker PM. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front Cardiovasc Med. 2019;6:16.
    1. Kotze MJ, Van Rensburg SJ. Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease. Metab Brain Dis. 2012;27:255–266.
    1. Whitmer RA, Gunderson EP, Barrett‐Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.
    1. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. New horizons in coronary heart disease Schwartz , Colin John and Born , Gustav VR. (Eds) Volume 5:1–5. London, England: Current Science, 1993.
    1. Saunders AM, Strittmatter WJ, Schmechel D, George‐Hyslop PS, Pericak‐Vance M, Joo S, Rosi B, Gusella J, Crapper‐MacLachlan D, Alberts M. Association of apolipoprotein E allele ε4 with late‐onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467–1472.
    1. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA. APOE, vascular pathology, and the AD brain. Neurology. 2005;65:259–265.
    1. Koran MEI, Wagener M, Hohman TJ; Alzheimer's Neuroimaging I . Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11:205–213.
    1. Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer's Disease Neuroimaging Initiative I . Sex modifies the APOE‐related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563–573.
    1. Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd‐Jones DM, Bae HJ, Bauman MA, Dichgans M, Duncan PW, Girgus M, Howard VJ, Lazar RM, Seshadri S, Testai FD, van Gaal S, Yaffe K, Wasiak H, Zerna C. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke. 2017;48:e284–e303.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅